On behalf of the ASTCT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Amrita Krishnan, MD, and William A. Wood, MD.

Question Title

* 1. According to expert opinion (2019) from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT; now American Society for Transplantation and Cellular Therapy [ASTCT]) which of the following is the recommended strategy to manage bridging chemotherapy or radiotherapy between T-cell collection by leukapheresis and infusion of tisagenlecleucel infusion in patients with relapsed or refractory B cell acute lymphoblastic leukemia?

Question Title

* 2. Which of the following statements about lymphodepleting chemotherapy prior to tisagenlecleucel infusion in patients with relapsed and refractory B cell acute lymphoblastic leukemia is CORRECT?

Question Title

* 3. In ELIANA trial, tisagenlecleucel infusion was given how many days after completion of lymphodepleting chemotherapy?

Question Title

* 4. Myeloid growth factors are not recommended during what period of time after tisagenlecleucel infusion in patient treated for B cell relapsed or refractory acute lymphoblastic leukemia?

Question Title

* 5. Which statement about sequence of tisagenlecleucel infusion with blinatumomab is CORRECT?

T